(Q42978115)

English

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients

scientific article published on 2 March 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Shiho Miyase

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Katsuki Haraoka

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yoshihiro Ouchida

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yuko Morishita

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Shigetoshi Fujiyama

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

2 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1014-1021

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009).

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Peginterferon and ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleuk

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

A high-throughput SNP typing system for genome-wide association studies

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0560-9

21 January 2018

Identifiers

10.1007/S00535-012-0560-9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42978115&oldid=1975607472"